Investing in the Future of
Exosome Therapies
NurExone is addressing multi-billion dollar global markets with the first two central nervous system (CNS) indications focused on acute spinal cord injury and acute glaucoma. Each of these markets represent an area of tremendous unmet need, representing a combined patient population of over 1.5M globally
December 10th, 2025 | 10:00 AM ET
Meet the Speakers
Lior Shaltiel, PhD
Chief Executive Officer & Director
Dr Shaltiel is an entrepreneur and
an award-winning scientist with
extensive multidisciplinary international experience, specializing in chemical engineering, molecular biology, electrophysiology, pharmacology
and drug delivery systems.
Yoram Drucker
Co-founder & Chairman
Mr. Drucker is a serial entrepreneur
who has been active in the Israeli
biotech industry for 20+ years, founding several companies. His expertise is in management, start-ups, operations, business development and
product development.
Jacob Licht
CEO, Exo-Top Inc.
Jacob Licht currently serves as
Chief Executive Officer of Exo-Top Inc.
and as Vice President of Corporate Development at NurExone. He brings
over 20 years of leadership experience
in the biotech and specialty
pharmaceutical industries.
Why This Matters to Investors
The ExoTherapy platform not only provides optionality for NurExone for both their own therapeutic development but also for partnering with other companies who can leverage exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue. By loading exosomes with therapeutic compounds, nanodrugs are created with natural regenerative properties.
Additionally, there is currently no way to repair a damaged or bruised spinal cord nor a cure for glaucoma. Not only does NurExone provide the platform opportunity with their delivery, but their proof-of-concept indications are targeting areas where there is vocal support for more treatments options.
Investment Thesis Highlights
Blockbuster
Potential
First two indications
represent significant market opportunities with
blockbuster commercial
potential ($1B+)
Hybrid Platform Technology
Platform technology provides multiple revenue streams and optionality with partnering as
well as future in-house
clinical development
Positive
Early Data
Recently reported multiple positive outcomes from
preclinical studies, providing robust data package for US
IND submission
Global Presence
& Robust IP
Actively growing presence globally, including increased US presence both physically and in the capital markets, with a
robust IP portfolio
Briefing Agenda
30 Minutes of Substantive Content
Platform
Update
Providing the latest
insights on our technology
and path forward
Data
Deep Dive
Highlighting the recent updates around our strong preclinical trials
Establishing a
US Presence
A formal introduction to
Exo-Top, our US-based manufacturing facility
Live Q&A
Session
Direct access to
management team for
detailed questioning
ABOUT US
Where Nature Ends, NurExone Begins
NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets.
Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
